Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)

Market Cap	6.25B -7.9%
Revenue (ttm)	1.47B -30.1%
Net Income	-1.00B
EPS	-1.52
Shares Out	661.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,444,500
Average Volume	9,372,822
Open	9.72
Previous Close	9.41
Day's Range	9.33 - 9.72
52-Week Range	4.73 - 12.79
Beta	0.57
RSI	48.90
Earnings Date	Apr 29, 2026

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sarsae, juice soda, soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 2,769
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300147

Financial Performance

In 2024, Xiangxue Pharmaceutical's revenue was 1.86 billion, a decrease of -19.16% compared to the previous year's 2.30 billion. Losses were -858.56 million, 120.7% more than in 2023.